TrialFrontiers in endocrinology2023

Pharmacoeconomic analysis (CER) of Dulaglutide and Liraglutide in the treatment of patients with type 2 diabetes.

Yu Su et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.